Program
atirmociclib
Also written as “PF-07220060 + PF-07104091 combination dose escalation”, “PF-07220060” and “Atirmociclib”.
In Pfizer’s pipeline, CDK4 inhibitor
. Its studies are mostly in Breast Neoplasms · Liposarcoma · Hepatic Insufficiency, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 147 open or running | phase 3since Dec 11, 2024 | Sep 15, 2020 | Feb 26, 2027phase 2 · NCT05262400 |
| AstraZenecaits history only | 11 open or running | phase 2since Feb 16, 2026 | Feb 16, 2026 | Dec 28, 2027phase 2 · NCT07427394 |
| Hoffmann-La Rocheits history only | 11 open or running | phase 2since Jan 30, 2018 | Jan 30, 2018 | Sep 30, 2030phase 2 · NCT03424005 |
| Olema Pharmaceuticalsits history only | 11 open or running | phase 1since Aug 16, 2022 | Aug 16, 2022 | Dec 31, 2027phase 1 · NCT05508906 |
- Named in Pfizer’s own pipeline as
atirmociclib PF-07220060
, phase 3, as of Nov 3, 2026 (source).
Also a collaborator on its studies: Gilead Sciences, Arvinas Estrogen Receptor and Novartis.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Jan 30, 2018.
- Aug 16, 2022Olema Pharmaceuticals’ first study: phase 1 study in Breast NeoplasmsNew to Olema PharmaceuticalsOlema Pharmaceuticals · NCT05508906 · 190 enrolled · United States, Australia
- Jun 20, 2023Phase 1 study in Healthy ParticipantsPfizer · NCT05923411 · 113 enrolled · United States
- Oct 24, 2023Phase 2 study in Breast NeoplasmsPfizer · NCT06105632 · 333 enrolled · United States, Argentina, Australia and more
- Dec 13, 2023Phase 2 study in Breast NeoplasmsPfizer · NCT06206837 · 71 enrolled · United States, Belgium, Canada and more
- Jan 17, 2024Phase 1 study in Healthy ParticipantsPfizer · NCT06267963 · 12 enrolled · Netherlands
- Jun 13, 2024Phase 2 study in Breast NeoplasmsPfizer · NCT06465368 · 121 enrolled · United States, Australia, Belgium and more
- Aug 11, 2024Named atirmociclibINNProposed as its International Nonproprietary Name in WHO's List 131 · before, PF-07220060
- Dec 11, 2024Phase 3 study in Breast NeoplasmsPfizer · NCT06760637 · 1,035 enrolled · United States, Argentina, Australia and more
- Mar 20, 2025Phase 1 study in Healthy AdultsPfizer · NCT06897683 · 14 enrolled · United States
- Aug 12, 20252 phase 1 studiesPfizer · NCT07130097, NCT07160738
- Oct 8, 2025Phase 1 study in Healthy VolunteerPfizer · NCT07215078 · 72 enrolled · United States
- Feb 16, 2026AstraZeneca’s first study: phase 2 study in Advanced Breast CancerNew to AstraZenecaAstraZeneca · NCT07427394 · 24 planned · United States, United Kingdom
- Jun 24, 2026Phase 1 study in Hepatic InsufficiencyPfizer · NCT07677358 · 28 planned · United States
- Oct 16, 2026Phase 3 study in Breast NeoplasmsPfizer · NCT07890597 · 3,800 planned
- Oct 21, 2026Primary completion moved from 2026-09-23 to 2029-10-07Date moved laterphase 2 · +36 months · NCT04557449
Ahead
- Feb 26, 2027Primary completion: phase 2 study in Breast NeoplasmsPfizer · NCT05262400
- Aug 14, 2027Primary completion: phase 1 study in Hepatic InsufficiencyPfizer · NCT07677358
- Dec 28, 2027Primary completion: phase 2 study in Advanced Breast CancerAstraZeneca · NCT07427394
- Dec 31, 2027Primary completion: phase 1 study in Breast NeoplasmsOlema Pharmaceuticals · NCT05508906
TargetBeta
“CDK4 inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), with potential antineoplastic activity. Upon administration, atirmociclib selectively inhibits CDK4, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase tran…”NCIt, read by Claude
“An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), ”NCIt, by rule
Other programs on CDK4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| abemaciclibrule | Eli Lilly | phase 4 | 49 |
| palbociclibrule | Pfizer | phase 4 | 36 |
| trilaciclibrule | Pharmacosmos | phase 4 | 14 |
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| HRS-6209 | Jiangsu HengRui Medicine | phase 3 | 7 |
| CDK4 Inhibitor BGB-43395rule | BeOne Medicines | phase 3 | 4 |
| narazaciclibrule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
| CG-7321rule | chengdu-cynogen-bio-pharmaceutical-tech-co-ltd | phase 1 | 1 |
| nkt5097 cdk2rule | nikang-therapeutics-inc | phase 1 | 1 |
| TSL2109rule | China Resources Pharmaceutical Group | phase 1 | 1 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07890597Breast Neoplasms | 3 | Not yet recruiting | Pfizer | Apr 13, 2032 | 3,800 |
| NCT07677358Hepatic Insufficiency · United States | 1 | Recruiting | Pfizer | Aug 14, 2027 | 28 |
| NCT07427394Advanced Breast Cancer · United States, United Kingdom | 2 | Recruiting | AstraZeneca | Dec 28, 2027 | 24 |
| NCT07215078Healthy Volunteer · United States | 1 | Completed | Pfizer | Jul 21, 2026 | 72 |
| NCT07160738Breast Neoplasms · United States | 1 | Completed | Pfizer | Nov 24, 2025 | 25 |
| NCT07130097Healthy Participant · United States | 1 | Completed | Pfizer | Oct 26, 2025 | 35 |
| NCT06897683Healthy Adults · United States | 1 | Completed | Pfizer | May 11, 2025 | 14 |
| NCT06760637Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Jan 2, 2029 | 1,035 |
| NCT06465368Breast Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Pfizer | Jul 10, 2025 | 121 |
| NCT06267963Healthy Participants · Netherlands | 1 | Completed | Pfizer | Apr 12, 2024 | 12 |
| NCT06206837Breast Neoplasms · United States, Belgium, Canada and more | 2 | Active, not recruiting | Pfizer | Sep 5, 2025 | 71 |
| NCT06105632Breast Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Pfizer | Jan 12, 2026 | 333 |
| NCT05923411Healthy Participants · United States | 1 | Completed | Pfizer | Jun 23, 2024 | 113 |
| NCT05508906Breast Neoplasms · United States, Australia | 1 | Active, not recruiting | Olema Pharmaceuticals | Dec 31, 2027 | 190 |
| NCT05262400Breast Neoplasms · United States, Argentina, Brazil and more | 2 | Active, not recruiting | Pfizer | Feb 26, 2027 | 235 |
| NCT04557449Liposarcoma · United States, Argentina, China and more | 2 | Recruiting | Pfizer | Oct 7, 2029 | 430 |
| NCT03424005Breast Neoplasms · United States, Australia, France and more | 2 | Recruiting | Hoffmann-La Roche | Sep 30, 2030 | 1,132 |
How it is read
Names in the registry
- “PF-07220060 + PF-07104091 combination dose escalation”, 8 entries
- “PF-07220060”, 7 entries
- “Atirmociclib”, 5 entries
- “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
- “Single dose of PF-07220060 as first Tablet Formulation”, 2 entries
Codes read as this program: PF07220060.
Conditions, from the studies’ own filings
- Breast Neoplasms, 10 studies
- Liposarcoma, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.